NOAC9 - Circulating Tumor DNA Guided Follow-Up in Anal Cancer
About this study
This study investigates if circulating tumor DNA can improve the detection of early treatment failure or recurrence in localized squamous cell carcinoma of the anus (SCCA) after curative chemoradiotherapy thereby increasing the potential for cure. This will be done by comparing the standard follow-up program with ctDNA guided imaging follow-up. Secondly, the aim is to establish early interventions against late morbidities.
- Condition
- Anal Cancer
- Tested
- AMR B: HPV positive ctDNA guided imaging in follow-up
- Sponsor
- Aarhus University Hospital
Who can join
- Age
- 18 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 5
- Minimum age: 18 years
- Study condition: Anal Cancer
- Patients with SCCA eligible for definitive (chemo)radiotherapy
- ≥ 18 of years
- Written and oral consent
Exclusion 3
- Conditions that will contraindicate blood samples
- Conditions that will contraindicate a PET-CT scan.
- Potential lack of compliance to standard FU program and study participation.
Where
13 sites, 13 recruiting
Aarhus University Hospital
Aarhus, Denmark
Department of Oncology Herlev and Gentofte Hospital
Herlev, Capital Region of Denmark, Denmark
Department of Oncology, Vejle Hospital
Vejle, The Regions of Southern Denmark, Denmark
Tampere University Hospital
Tampere, Finland
Turku University Hospital
Turku, Finland
Haukeland University Hospital
Bergen, Norway
and 7 more sites on ClinicalTrials.gov
Contact
-
Karen-Lise G Spindler, Professor
91137244 k.g.spindler@rm.dk
-
Louise V Laursen, Secretary
78454979 louise@oncology.au.dk
Potential match only. Final eligibility is determined by the study team.